GPNMB (E4D7P) & CO-0132-647 SignalStar™ Oligo-Antibody Pair #82146
Filter:
- IHC
SignalStar™ multiplex immunohistochemical analysis of paraffin-embedded human lung adenocarcinoma using GPNMB (E4D7P) Rabbit mAb (488; green) and DAPI #4083 (blue). Staining was performed on the BOND RX autostainer by Leica Biosystems.
Order Information # 82146
This product is not sold separately. Please see the SignalStar™ Multiplex IHC Panel Builder Tool for ordering information.
- Product Includes
| Product Includes | Volume | Reactivity | Isotype |
|---|---|---|---|
| GPNMB (E4D7P) XP® Rabbit mAb (SignalStar™ Conjugate 0132) #83540 | 50 µl | H | Rabbit IgG |
| Complementary Oligo (CO-0132-647) #38315 | 22 µl |
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| SignalStar™ Leica Bond | 1:50 - 1:200 |
| SignalStar™ Manual | 1:50 - 1:200 |
Storage
SignalStar conjugates are supplied in PBS (pH 7.2), less than 0.1% sodium azide, 2 mM EDTA, 0.05% Triton X-100, 2 mg/mL BSA, and 50% glycerol. Complementary oligos are supplied in nuclease-free water. Store at -20°C. Do not aliquot the antibody. All components in this kit are stable for at least 12 months when stored at the recommended temperature.
Product Description
SignalStar multiplex immunohistochemistry (IHC) is an advanced technology for labeling multiple proteins simultaneously in tissue samples using specific primary antibodies and fluorescent detection reagents. This technology offers accuracy and reliability in visualizing and analyzing protein expression while maintaining spatial context and tissue architecture.
SignalStar Oligo-Antibody Pairs are compatible with the SignalStar Multiplex IHC Buffer Kits for use in fluorescent multiplex imaging experiments. This product includes the oligo-conjugated antibodies and complementary oligos required for labeling your target protein on up to 10 slides. SignalStar Multiplex IHC Buffer Kits are required to amplify and image the target signal. Multiple oligo-antibody pairs can be conveniently combined into a multiplex panel using the SignalStar Multiplex IHC Panel Builder. SignalStar Multiplex IHC Kits & Reagents are not compatible with all of Cell Signaling Technology® products and protocols that are recommended for use in immunohistochemical assays.
SignalStar Oligo-Antibody Pairs are compatible with the SignalStar Multiplex IHC Buffer Kits for use in fluorescent multiplex imaging experiments. This product includes the oligo-conjugated antibodies and complementary oligos required for labeling your target protein on up to 10 slides. SignalStar Multiplex IHC Buffer Kits are required to amplify and image the target signal. Multiple oligo-antibody pairs can be conveniently combined into a multiplex panel using the SignalStar Multiplex IHC Panel Builder. SignalStar Multiplex IHC Kits & Reagents are not compatible with all of Cell Signaling Technology® products and protocols that are recommended for use in immunohistochemical assays.
Protocol
Specificity / Sensitivity
GPNMB (E4D7P) XP® Rabbit mAb (SignalStar™ Conjugate 0132) recognizes endogenous levels of total GPNMB protein. Based upon sequence alignment, this antibody is not predicted to cross-react with PMEL.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human GPNMB protein.
Background
Glycoprotein non-metastatic gene B (GPNMB) is a type I transmembrane glycoprotein overexpressed in many types of cancer. The GPNMB glycoprotein is involved in many physiological processes, including mediating transport of late melanosomes to keratinocytes (1), regulating osteoblast and osteoclast differentiation and function (2), stimulating dendritic cell maturation, promoting adhesion of dendritic cells to endothelial cells (3), enhancing autophagosome fusion to lysosomes in tissue repair, and regulating degradation of cellular debris (4,5).
While typical GPNMB expression is seen in tissues including skin, heart, kidney, lung, liver, and skeletal muscle (3,6), research studies show elevated GPNMB expression often contributes to the metastatic phenotype in numerous cancers (reviewed in 7). GPNMB is typically localized to intracellular compartments in normal cells (1,8), but investigators found it primarily on the cell surface of tumor cells (9,10). Differential localization and expression, and the role of GPNMB as a tumor promoter in many cancer types make this protein a viable therapeutic target (11).
The GPNMB ectodomain can be cleaved by matrix metalloproteinases and shed from the cell surface (12). Research studies identify the sheddase ADAM10 as one peptidase responsible for cleavage of the GPNMB ectodomain at the surface of breast cancer cells. Shedded GPNMB ectodomains may promote angiogenesis by inducing endothelial cell migration (13).
While typical GPNMB expression is seen in tissues including skin, heart, kidney, lung, liver, and skeletal muscle (3,6), research studies show elevated GPNMB expression often contributes to the metastatic phenotype in numerous cancers (reviewed in 7). GPNMB is typically localized to intracellular compartments in normal cells (1,8), but investigators found it primarily on the cell surface of tumor cells (9,10). Differential localization and expression, and the role of GPNMB as a tumor promoter in many cancer types make this protein a viable therapeutic target (11).
The GPNMB ectodomain can be cleaved by matrix metalloproteinases and shed from the cell surface (12). Research studies identify the sheddase ADAM10 as one peptidase responsible for cleavage of the GPNMB ectodomain at the surface of breast cancer cells. Shedded GPNMB ectodomains may promote angiogenesis by inducing endothelial cell migration (13).
- Tomihari, M. et al. (2009) Exp Dermatol 18, 586-95.
- Sheng, M.H. et al. (2012) PLoS One 7, e35280.
- Shikano, S. et al. (2001) J Biol Chem 276, 8125-34.
- Li, B. et al. (2010) FASEB J 24, 4767-81.
- Patel-Chamberlin, M. et al. (2011) Kidney Int 79, 1138-48.
- Bandari, P.S. et al. (2003) Regul Pept 111, 169-78.
- Maric, G. et al. (2013) Onco Targets Ther 6, 839-52.
- Ripoll, V.M. et al. (2007) J Immunol 178, 6557-66.
- Tse, K.F. et al. (2006) Clin Cancer Res 12, 1373-82.
- Rose, A.A. et al. (2010) Clin Cancer Res 16, 2147-56.
- Keir, C.H. and Vahdat, L.T. (2012) Expert Opin Biol Ther 12, 259-63.
- Furochi, H. et al. (2007) FEBS Lett 581, 5743-50.
- Rose, A.A. et al. (2010) PLoS One 5, e12093.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
SignalStar is a registered trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 10,781,477, foreign equivalents, and child patents deriving therefrom.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.